BeiGene’s PD-1 Remains Solid In First Global Pivotal Study
Positive Interim Data In Later-Line NSCLC
Tislelizumab meets overall survival endpoint in later-line NSCLC at planned interim analysis, but faces exploding competition in the Chinese immuno-oncology sector.
You may also be interested in...
The Chinese biotech is set to extend the reach of its PD-1 candidate to the global market with a second major clinical win and following an earlier major deal with Novartis.
Lilly is acquiring exclusive global rights to a Chinese domestically developed immuno-oncology drug in one of the year’s biggest commercial deals in the country.
In this week's podcast edition of Five Must-Know Things: a ground-breaking approval for Alzheimer’s in the US; LAG-3 inhibitors and new Keytruda data generate excitement at ASCO; and clinical progress for another COVID-19 vaccine.